A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care
Open Access
- 13 April 2013
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 4 (4) , 502-530
Abstract
To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are aprepitant, artesunate, auranofin, captopril, copper gluconate, disulfiram, ketoconazole, nelfinavir, sertraline, to be added to continuous low dose temozolomide. We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma’s compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed.Keywords
This publication has 310 references indexed in Scilit:
- Critical multiple angiogenic factors secreted by glioblastoma stem‐like cells underline the need for combinatorial anti‐angiogenic therapeutic strategiesProteomics – Clinical Applications, 2013
- Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implicationsExperimental Cell Research, 2012
- Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsBiochemical Pharmacology, 2012
- Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgeryJournal of Neuro-Oncology, 2012
- The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistanceChemico-Biological Interactions, 2012
- Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastomaJournal of Neuro-Oncology, 2011
- A HIF-1 Target, ATIA, Protects Cells from Apoptosis by Modulating the Mitochondrial Thioredoxin, TRX2Molecular Cell, 2011
- Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growthThe Prostate, 2010
- A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate CancerJournal of Urology, 2010
- Ni(II), Cu(II), and Zn(II) Diethyldithiocarbamate Complexes Show Various Activities Against the Proteasome in Breast Cancer CellsJournal of Medicinal Chemistry, 2008